Psychiatrists’ attitude towards and knowledge of clozapine treatment

@article{Nielsen2010PsychiatristsAT,
  title={Psychiatrists’ attitude towards and knowledge of clozapine treatment},
  author={Jimmi Nielsen and M Dahm and Henrik K F Lublin and David Taylor},
  journal={Journal of Psychopharmacology},
  year={2010},
  volume={24},
  pages={965 - 971}
}
Clozapine is, in most countries, underutilized and the initiation of clozapine is often delayed. The purpose of this study is to investigate the reasons for the delay and the underutilization of clozapine. One hundred psychiatrists were interviewed by phone. The interview was a structured interview with questions regarding attitude to, knowledge of and experiences with clozapine. Forty-eight (48%) psychiatrists had treatment responsibility of fewer than five patients treated with clozapine and… 

Figures from this paper

Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey

In general, psychiatrists in Serbia seem to be confident in prescribing clozapine, even in the absence of clear monitoring guidelines and the possibility of therapeutic drug monitoring, according to a nation-wide assessment of both the psychiatrists’ attitudes of the obstacles for prescriptions and their prescription practices.

Clozapine prescribing in the UK: views and experience of consultant psychiatrists

Important areas of concern such as managing side effects and deficiency in evidence-based use of clozapine were identified and can be targeted in training and professional development programme.

Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey.

Findings of this study support the need for continued clozapine education regardless of a prescriber's age/experience, and future studies to assess barriers to clozAPine prescribing should extend beyond academic centers.

Iranian psychiatrists’ attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey

Iranian psychiatrists had a good self-perception of knowledge about the efficacy of clozapine for patients with TRS, but concerns about serious side effects are common.

A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists

Continuing professional education on clozapine are needed for psychiatrists who see individuals with psychotic disorders and in comparison to the AACP, the SSCA group felt less comfortable, perceived clozamine as less safe and effective, and were more likely to prefer antipsychotic polypharmacy to clozAPine use.

Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol

A scoping review is warranted in order to map and synthesise primary literature on patients’ and psychiatrists’ perspectives on clozapine treatment, and to identify gaps for future research.

Prescribers fear as a major side‐effect of clozapine

  • D. Cohen
  • Psychology, Medicine
    Acta psychiatrica Scandinavica
  • 2014
The data indicate that clozapine is accompanied not by the worst but by the best (and longest) compliance, and safety issues, by some considered as obstacles to clozAPine initiation, can be broken down into three treatment-emergent side-effects.
...

References

SHOWING 1-10 OF 43 REFERENCES

Clozapine - a survey of patient perceptions

It is suggested that clozapine is effective as assessed by patients' own standards and that adherence to therapy is likely to be good, and patients stabilised on clozAPine are largely content with their treatment.

Patients' and relatives' assessment of clozapine treatment

Patients and relatives frequently hold specific and distinct views on clozapine treatment, and these views should be considered when patients and relatives are informed and when compliance is addressed.

Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.

Clozapine Treatment of Adolescents With Posttraumatic Stress Disorder and Psychotic Symptoms

Findings indicate that clozapine may be effective in decreasing psychiatric symptoms and risk behaviors in traumatized adolescents presenting with psychotic symptoms in treatment-resistant abused adolescents detained in a secure environment.

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.

Clozapine treatment was quite likely delayed for longer than is clinically desirable and this delay may have important effects on quality of life, clinical outcome, and health resource utilization.

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders

This case series underlines the safety and efficacy of clozapine as add-on medication in the treatment of bipolar and schizoaffective disorders.

Long-term experience with clozapine in Denmark: research and clinical practice

In Denmark, the use of clozapine has increased markedly (15–25% per year) since 1983, when the drug was relaunched — after its withdrawal in 1975. Several factors have contributed to this

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.

In people with schizophrenia with poor treatment response to 2 or more antipsychotic drugs, there is an advantage to commencing clozapine rather than other SGA drugs in terms of symptom improvement over 1 year.

Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

The addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia, and there was no statistically significant difference in symptomatic benefit between augmentation with ris peridone and placebo.